0RHR Stock Overview
A biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kuros Biosciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 24.08 |
| 52 Week High | CHF 31.85 |
| 52 Week Low | CHF 3.16 |
| Beta | 0.76 |
| 11 Month Change | -3.12% |
| 3 Month Change | 58.18% |
| 1 Year Change | 535.22% |
| 33 Year Change | 1,103.75% |
| 5 Year Change | n/a |
| Change since IPO | -14.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RHR | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.3% | 0.3% | 2.2% |
| 1Y | 535.2% | -18.3% | 8.0% |
Return vs Industry: 0RHR exceeded the UK Biotechs industry which returned -18.3% over the past year.
Return vs Market: 0RHR exceeded the UK Market which returned 8% over the past year.
Price Volatility
| 0RHR volatility | |
|---|---|
| 0RHR Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RHR's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RHR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 106 | Chris Fair | www.kuros.ch |
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft.
Kuros Biosciences AG Fundamentals Summary
| 0RHR fundamental statistics | |
|---|---|
| Market cap | CHF 913.02m |
| Earnings (TTM) | -CHF 8.89m |
| Revenue (TTM) | CHF 52.54m |
17.4x
P/S Ratio-102.7x
P/E RatioIs 0RHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RHR income statement (TTM) | |
|---|---|
| Revenue | CHF 52.54m |
| Cost of Revenue | CHF 6.43m |
| Gross Profit | CHF 46.11m |
| Other Expenses | CHF 55.00m |
| Earnings | -CHF 8.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 87.77% |
| Net Profit Margin | -16.91% |
| Debt/Equity Ratio | 0% |
How did 0RHR perform over the long term?
See historical performance and comparison